Bioherent

Bioherent is a biotechnology company founded in 2021 as a spin-off from the University of Málaga, Spain. The company focuses on developing advanced in vitro diagnostic devices that utilize integrated photonic biosensors, nanomaterials, and specialized surface chemistry. Its mission is to enhance drug allergy diagnostics, providing fast and accurate testing solutions that improve patient outcomes and address antimicrobial resistance. The flagship product, AllerWAVE®, is a diagnostic platform designed for the sensitive detection of antibiotic allergies, particularly to betalactam antibiotics like penicillin. This compact tabletop analyzer, paired with disposable cartridges, allows for label-free and ultra-sensitive biomarker detection without the need for specialized personnel. By reducing diagnostic time and costs, AllerWAVE® aims to minimize the high rate of misdiagnosis associated with betalactam allergies. Bioherent's team comprises researchers from various fields, including photonics, organic chemistry, and immunology, driving innovation in photonic biosensing technology. The company primarily serves healthcare providers, hospitals, and clinical laboratories, offering reliable and efficient diagnostic tools for drug allergy testing.

• Employees 13
• Founded 2021